HTG Announces Preliminary Full Year 2018 Unaudited Revenue of Approximately $21.5 Million

TUCSON, Jan. 07, 2019 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced preliminary, unaudited financial results for the full year ended December 31, 2018 .